The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients
Abstract
We reviewed 200 patients with paraneoplastic encephalomyelitis (PEM) and anti-Hu antibodies to show possible clinical differences with respect to previous series, and to identify patient, tumour and treatment-related characteristics associated with neurological disability and survival. The median age of the 200 patients was 63 years (range 28-82 years) and 75% were men. The predominant neurological syndromes were sensory neuropathy (54%), cerebellar ataxia (10%), limbic encephalitis (9%) and multifocal involvement (11%). Sensorimotor neuropathies with predominant motor involvement were observed in only 4% of the patients. Pathological or X-ray evidence of a tumour was obtained in 167 patients (83%) and was a small-cell lung cancer (SCLC) in 74% of those with histological diagnosis. Coexistence of extrathoracic tumours with SCLC was rare (0.5%). Positive Hu immunoreactivity was observed in the extrathoracic tumours of six out of seven patients in whom autopsy or long-term follow-up ruled out a coexisting SCLC. PEM preceded the diagnosis of the tumour in 71% of patients (mean delay +/- SD 6.5 +/- 7.0 months; range 0.1-47 months). In the 24 patients in whom the tumour diagnosis was the initial event, PEM predicted the progression or relapse of the tumour in 87% of them. No tumour was found in 33 patients, including four who had a post-mortem study and four with >5 years of follow-up. In a logistic regression analysis, treatment of the tumour, associated or not with immunotherapy, was an independent predictor of improvement/stabilization of PEM [odds ratio 4.56; 95% confidence interval (CI) 1.62-12.86]. Cox multivariate analysis indicated that the variables independently associated with mortality were: age >60 years [relative risk (RR) 1.49; 95% CI 1.05-2.12], Rankin score at diagnosis >3 (RR 1.60; 95% CI 1.12-2.28), more than one area of the nervous system affected (RR 1.61; 95% CI 1.08-2.40), and absence of treatment (RR 2.56; 95% CI 1.76-3.71). We conclude that, unlike previous series, the majority of our patients were male, and there was a low occurrence of predominantly motor neuropathies and extrathoracic tumours coexisting with SCLC. When the diagnosed extrathoracic tumour expresses Hu antigens, further tests to rule out a coexisting SCLC are probably unnecessary. Finally, the predictors of mortality and PEM evolution found in the study may be important in the design of future therapeutic protocols, and emphasize the importance of early diagnosis and treatment of the underlying tumour.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1990) · Choice Reviews Online · doi:10.5860/choice.27-3338 · Cited by 35,305
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Turrisi, A. T., Kim, K., Blum, R., Sause, W. T., Livingston, R. B., Komaki, R., Wagner, H., Aisner, S., & Johnson, D. H. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901283400403 · Cited by 1,506
Preoperative Staging of Non–Small-Cell Lung Cancer with Positron-Emission Tomography
Pieterman, R. M., van Putten, J. W. G., Meuzelaar, J. J., Mooyaart, E. L., Vaalburg, W., Koëter, G. H., Fidler, V., Pruim, J., & Groen, H. J. M. (2000) · New England Journal of Medicine · doi:10.1056/nejm200007273430404 · Cited by 1,111
Dalmau, J., Graus, F., Rosenblum, M. K., & Posner, J. B. (1992) · MEDICINE · doi:10.1097/00005792-199203000-00001 · Cited by 819
Self-citationTHE LAMBERT-EATON MYASTHENIC SYNDROME: A REVIEW OF 50 CASES
O'NEILL, J. H., MURRAY, N. M. F., & NEWSOM-DAVIS, J. (1988) · Brain · doi:10.1093/brain/111.3.577 · Cited by 686
Szabo, A., Dalmau, J., Manley, G., Rosenfeld, M., Wong, E., Henson, J., Posner, J. B., & Furneaux, H. M. (1991) · Cell · doi:10.1016/0092-8674(91)90184-z · Cited by 553
Lucchinetti, C. F., Kimmel, D. W., & Lennon, V. A. (1998) · Neurology · doi:10.1212/wnl.50.3.652 · Cited by 499
Dalmau, J., Furneaux, H. M., Gralla, R. J., Kris, M. G., & Posner, J. B. (1990) · Annals of Neurology · doi:10.1002/ana.410270515 · Cited by 393
PRIMARY SENSORY NEUROPATHY WITH MUSCULAR CHANGES ASSOCIATED WITH CARCINOMA
Denny-Brown, D. (1948) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.11.2.73 · Cited by 380
Cited by
Paraneoplastic anti– N ‐methyl‐ D ‐aspartate receptor encephalitis associated with ovarian teratoma
Dalmau, J., Tüzün, E., Wu, H., Masjuan, J., Rossi, J. E., Voloschin, A., Baehring, J. M., Shimazaki, H., Koide, R., King, D., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21050 · Cited by 2,492
Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis
Dalmau, J., Lancaster, E., Martinez-Hernandez, E., Rosenfeld, M. R., & Balice-Gordon, R. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70253-2 · Cited by 2,435
Recommended diagnostic criteria for paraneoplastic neurological syndromes
Graus, F. (2004) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.034447 · Cited by 1,610
Self-citationIrani, S. R., Alexander, S., Waters, P., Kleopa, K. A., Pettingill, P., Zuliani, L., Peles, E., Buckley, C., Lang, B., & Vincent, A. (2010) · Brain · doi:10.1093/brain/awq213 · Cited by 1,359
Paraneoplastic Syndromes Involving the Nervous System
Darnell, R. B., & Posner, J. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmra023009 · Cited by 1,062
Vincent, A., Buckley, C., Schott, J. M., Baker, I., Dewar, B., Detert, N., Clover, L., Parkinson, A., Bien, C. G., Omer, S., et al. (2004) · Brain · doi:10.1093/brain/awh077 · Cited by 1,038
Irani, S. R., Bera, K., Waters, P., Zuliani, L., Maxwell, S., Zandi, M. S., Friese, M. A., Galea, I., Kullmann, D. M., Beeson, D., et al. (2010) · Brain · doi:10.1093/brain/awq113 · Cited by 1,035
“had a score of 5 [severe disability with total dependency requiring constant attention (Graus et al., 2001)] at peak of disease, and average duration of hospitalization was 160 days (range 16–850).”
InfluentialParaneoplastic syndromes of the CNS
Dalmau, J., & Rosenfeld, M. R. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70060-7 · Cited by 873
Clinical analysis of anti-Ma2-associated encephalitis
Dalmau, J. (2004) · Brain · doi:10.1093/brain/awh203 · Cited by 771
Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes
Graus, F., Vogrig, A., Muñiz-Castrillo, S., Antoine, J.-C. G., Desestret, V., Dubey, D., Giometto, B., Irani, S. R., Joubert, B., Leypoldt, F., et al. (2021) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000001014 · Cited by 759
Self-citationImmunopathology of autoantibody-associated encephalitides: clues for pathogenesis
Bien, C. G., Vincent, A., Barnett, M. H., Becker, A. J., Blumcke, I., Graus, F., Jellinger, K. A., Reuss, D. E., Ribalta, T., Schlegel, J., et al. (2012) · Brain · doi:10.1093/brain/aws082 · Cited by 695
Self-citationChemotherapy‐induced neuropathy
Windebank, A. J., & Grisold, W. (2008) · Journal of the Peripheral Nervous System · doi:10.1111/j.1529-8027.2008.00156.x · Cited by 613
Shams’ili, S., Grefkens, J., de Leeuw, B., van den Bent, M., Hooijkaas, H., van der Holt, B., Vecht, C., & Sillevis Smitt, P. (2003) · Brain · doi:10.1093/brain/awg133 · Cited by 579
Autoantibodies associated with diseases of the CNS: new developments and future challenges
Vincent, A., Bien, C. G., Irani, S. R., & Waters, P. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70096-5 · Cited by 542
Screening for tumours in paraneoplastic syndromes: report of an EFNS Task Force
Titulaer, M. J., Soffietti, R., Dalmau, J., Gilhus, N. E., Giometto, B., Graus, F., Grisold, W., Honnorat, J., Sillevis Smitt, P. A. E., Tanasescu, R., et al. (2011) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03220.x · Cited by 526
Self-citationTreatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates
Ances, B. M., Vitaliani, R., Taylor, R. A., Liebeskind, D. S., Voloschin, A., Houghton, D. J., Galetta, S. L., Dichter, M., Alavi, A., Rosenfeld, M. R., et al. (2005) · Brain · doi:10.1093/brain/awh526 · Cited by 488
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Ganti, A. K. P., Loo, B. W., Bassetti, M., Blakely, C., Chiang, A., D'Amico, T. A., D'Avella, C., Dowlati, A., Downey, R. J., Edelman, M., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0058 · Cited by 486
Limbic Encephalitis and Variants: Classification, Diagnosis and Treatment
Tüzün, E., & Dalmau, J. (2007) · The Neurologist · doi:10.1097/nrl.0b013e31813e34a5 · Cited by 478
The Diagnosis and Treatment of Autoimmune Encephalitis
Lancaster, E. (2016) · Journal of Clinical Neurology · doi:10.3988/jcn.2016.12.1.1 · Cited by 437
Kalemkerian, G. P., Akerley, W., Bogner, P., Borghaei, H., Chow, L. Q., Downey, R. J., Gandhi, L., Ganti, A. K. P., Govindan, R., Grecula, J. C., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0011 · Cited by 436
Leypoldt, F., Armangue, T., & Dalmau, J. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12553 · Cited by 416
Lambert–Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies
Titulaer, M. J., Lang, B., & Verschuuren, J. J. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70245-9 · Cited by 408
Antibodies and neuronal autoimmune disorders of the CNS
Graus, F., Saiz, A., & Dalmau, J. (2010) · Journal of Neurology · doi:10.1007/s00415-009-5431-9 · Cited by 392
Self-citationParaneoplastic Neurologic Syndrome in the PNS Euronetwork Database: A European Study From 20 Centers
Giometto, B. (2010) · Archives of Neurology · doi:10.1001/archneurol.2009.341 · Cited by 373
Autoimmune Epilepsy: Clinical Characteristics and Response to Immunotherapy
Quek, A. M. L. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.2985 · Cited by 359
Paraneoplastic neurological syndromes
Honnorat, J., & Antoine, J.-C. (2007) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-2-22 · Cited by 357
Autoimmune Encephalitis: Pathophysiology and Imaging Review of an Overlooked Diagnosis
Kelley, B. P., Patel, S. C., Marin, H. L., Corrigan, J. J., Mitsias, P. D., & Griffith, B. (2017) · American Journal of Neuroradiology · doi:10.3174/ajnr.a5086 · Cited by 310
Zuliani, L., Graus, F., Giometto, B., Bien, C., & Vincent, A. (2012) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2011-301237 · Cited by 293
Self-citationMolecular and clinical diversity in paraneoplastic immunity to Ma proteins
Rosenfeld, M. R., Eichen, J. G., Wade, D. F., Posner, J. B., & Dalmau, J. (2001) · Annals of Neurology · doi:10.1002/ana.1288 · Cited by 291
Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors
Graus, F., & Dalmau, J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0194-4 · Cited by 276
Self-citationHonnorat, J., Cartalat-Carel, S., Ricard, D., Camdessanche, J. P., Carpentier, A. F., Rogemond, V, Chapuis, F., Aguera, M., Decullier, E., Duchemin, A. M., et al. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.138016 · Cited by 272
Self-citationGABA B receptor antibodies in limbic encephalitis and anti-GAD–associated neurologic disorders
Boronat, A., Sabater, L., Saiz, A., Dalmau, J., & Graus, F. (2011) · Neurology · doi:10.1212/wnl.0b013e31820e7b8d · Cited by 271
Self-citationAutonomic peripheral neuropathy
Freeman, R. (2005) · The Lancet · doi:10.1016/s0140-6736(05)74815-7 · Cited by 270
The pattern and diagnostic criteria of sensory neuronopathy: a case-control study
Camdessanche, J.-P., Jousserand, G., Ferraud, K., Vial, C., Petiot, P., Honnorat, J., & Antoine, J.-C. (2009) · Brain · doi:10.1093/brain/awp136 · Cited by 262
Paraneoplastic peripheral neuropathy associated with anti‐Hu antibodies
Camdessanché, J., Antoine, J., Honnorat, J., Vial, C., Petiot, P., Convers, P., & Michel, D. (2002) · Brain · doi:10.1093/brain/awf006 · Cited by 254
Psychiatric Manifestations of Paraneoplastic Disorders
Kayser, M. S., Kohler, C. G., & Dalmau, J. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09101547 · Cited by 129
Paraneoplastic neuropathy: wide-ranging clinicopathological manifestations
Koike, H., Tanaka, F., & Sobue, G. (2011) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32834a87b7 · Cited by 105
Wesselingh, R., Butzkueven, H., Buzzard, K., Tarlinton, D., O'Brien, T. J., & Monif, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02066 · Cited by 83
“Immunotherapy alone in these patients is unlikely to be successful in the long-term (69).”
Background
Metadata
- Authors
- Graus, F.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2001-06-01
- Volume
- 124
- Issue
- 6
- Pages
- 1138-1148
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2124472369
- Cited by
- 897
- References
- 30
- FWCI
- 18.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.